improvements to PSMA-617 PET may be ... - Advanced Prostate...

Advanced Prostate Cancer

21,806 members27,295 posts

improvements to PSMA-617 PET may be on the way using 89 Zr and DMSO

Graham49 profile image
3 Replies

Nuclear Medicine and Biology

Volumes 106–107, March–April 2022, Pages 21-28

Radiolabeling of PSMA-617 with 89Zr: A novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results

Author links open overlay panelRyotaImuraabcYoshitakaKumakurae

doi.org/10.1016/j.nucmedbio...

Get rights and content

Highlights

•89Zr-PSMA-617 was achieved for the first time by using a HEPES buffer with DMSO.

•89Zr-PSMA-617 allowed visualization of PSMA-positive tumors.

•The radiolabel did not accumulate in the bladder at 24 h post-injection.

•89Zr-PSMA-617 could be an optimum choice for dosimetry of 177Lu-PSMA-617.

abstract

Introduction

Novel diagnostic and therapeutic options are urgently needed for patients with metastatic castration-resistant prostate cancer (CRPC). PSMA-617 is one of the most promising ligands that bind to prostate specific membrane antigen (PSMA), the cell surface biomarker of CRPC. Of the radiolabeled PSMA ligands developed to date, [68Ga]Ga-PSMA-617 is most commonly used for PSMA positron emission tomography (PET) prior to radioligand therapy (RLT) with [177Lu]Lu-PSMA-617. However, the presence of 68Ga radioactivity (half-life 68 m) in urine at the early PET imaging time point complicates optimization of the therapeutic dose of PSMA-617 labeled with 177Lu (half-life 6.7 d). Thus, PET imaging with the long-lived positron emitter 89Zr (half-life 3.3 d) would be better suited in order to optimize the dose of [177Lu]Lu-PSMA-617 as 89Zr PET allows scans after excretion of the radioactive urine. Until now, PSMA -617 could not be radiolabeled with 89Zr with high radiochemical yield due to poor incorporation of 89Zr into 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Here we report a novel method for radiolabeling PSMA-617 with 89Zr and the preliminary results of small-animal PET with [89Zr]Zr-PSMA-617.

Written by
Graham49 profile image
Graham49
To view profiles and participate in discussions please or .
Read more about...
3 Replies
TJGuy profile image
TJGuy

I see this article came from Japan.

I posted about zirconium 89 earlier this year on this sight. The article I posted was from Germany, and testing had been performed on people.

I forwarded to my DR at MAYO to see if they would use scan results for treatment and they did not reccomend it.

I mentioned this to my MO who said he was up on everything new and hadn't heard of it.

I contacted the German doctor to receive the scan and was given the ok to participate. I am awaiting answers to questions before participating. Probably will scheduled concurrently with PSMA Pylarify scan at Mayo.

Cost in Germany was 2500 euros with scans over three days.

I

Graham49 profile image
Graham49 in reply to TJGuy

Thanks for posting.

Rickmartin1948 profile image
Rickmartin1948

That is very interesting and thanks foir n sharing. Also in my last PETST scans I have been using or the radiologist has been using 18-F which has similar sensitivity as GA68 and a longer half life which allows to clear the bladder before imaging

Not what you're looking for?

You may also like...

My 80 year-old dad with MPCa, broke his leg and now seems to be giving up. Advice on best anti-anxiety meds desperately needed.

Dear PC family As you will see from my profile my dad in England has been on his prostate cancer...

Stage 4 A Prostate cancer

My partner was diagnosed with stage 4 A prostate cancer with spread to pelvic lymph nodes....

THIS IS NOT GOOD over 40 Liver Lesions

ON PET SCAN THEY FOUND 3 stating not psma avid on MRI stating they are psma avid How bad is this...

Pet Scan Below, Does Non Avid PSMA Liver Lesions mean possible Neuroendocrine Cancer

EXAM: PET-CT SKULL BASE TO MID-THIGH   CLINICAL HISTORY: Metastatic prostate cancer, rising...

Clarity Update: Complete response in first patient ever treated with 2 doses of Cu-67 SAR-bisPSMA at 8GBq

Highlights A complete response, based on Response Evaluation Criteria In Solid Tumours (RECIST...